Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells

Blood

Volumn 88, Issue 11, 1996, Pages 4275-4287

  Rajapaksa, Ranjani ^b   Ginzton, Nancy ^b   Rott, Lusijah S ^b   Greenberg, Peter L ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DNA FRAGMENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; MYC PROTEIN; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CYCLE; CELL DEATH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DNA CONTENT; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0029957664     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.11.4275.4275     Document Type: Article

References (62)

1. Saarni MI, Linman JW: Preleukemia the hematologic syndrome preceding acute leukemia. Am J Med 55:38, 1973
2. Linman JW, Bagby GC: The preleukemic syndrome: (hemopoetic dysplasia). Cancer 42:854, 1978
3. Greenberg PL: The smoldering myeloid leukemic states: clinical and biologic features. Blood 61:1035, 1983
4. Greenberg PL, Mara B: The preleukemic syndrome. Correlation of in vitro parameters of granulopoiesis with clinical features. Am J Med 66:951, 1979
5. Greenberg PL: Treatment of myelodysplastic syndrome. Blood Rev 5:42, 1991.
6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189, 1982
7. Koeffler HP: Myelodysplastic syndromes (preleukemia). Semin Hematol 23: 284, 1986
8. Wyllie AH: Cell death. Int Rev Cytol 17:755, 1987
9. Wyllie AH, Kerr JFR, Currie AH: Cell death the significance of apoptosis. Int Rev Cytol 68:251, 1980
10. Walker NI, Harmon BV, Gobe GC, Kerr JFR: Patterns of cell death. Methods Achiev Exp Pathol 13:18, 1988
11. Cohen JJ, Duke RC: Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 123:3842, 1984
12. Wyllie AH: Glucocorticoid-induced thymocyte apoptosis is associated with endonuclease activation. Nature 284:555, 1980
13. Vaux D: Toward understanding of the molecular mechanism of physiological cell death. Proc Natl Acad Sci USA 90:786, 1993
14. McDonnell TJ, Deane N, Plan FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ: Bcl-2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular proliferation. Cell 57:79, 1989
15. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119, 1992
16. Askew DS, Ashmun RA, Simmons BC, Cleveland JL: Constitutive c-myc expression in IL-3 dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6:1915, 1991
17. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847, 1993
18. Chen-Levy Z, Nourse J, Cleary ML: The bcl-2 candidate protooncogene product is a 24-kilodalton integral memrane protein highly expressed in lymphoid cell lines and lymphoma carrying the t(14;18) translocation. Molec Cell Biol 9:701, 1989
19. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334, 1990
20. Nunez G, London L, Hockenbery D, Alexander M, McKern JP, Korsmeyer SJ: Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor deprived hematopoietic cells. J Immunol 144:3604, 1990
21. Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440, 1988
22. Fanidi A, Harrington EA, Evan GI: Interaction between c-myc and bcl-2 protooncogenes: A noval paradigm for oncogene cooperation. Nature 359:554, 1992
23. Bissonnette RP, Echeverrri F, Mahboudi A, Green DR: Apoptotic cell death induced by c- myc is inhibited by bcl-2. Nature 359:552, 1992
24. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR: Role for c-myc in activation induced apoptotic cell death in T-cell hybridomas. Science 257:213, 1992
25. Clark DM, Lampert IA: Apoptosis is a common histopathological finding in myelodysplasia: The correlate of ineffective haematopoiesis. Leuk Lymphoma 2:415, 1990
26. Raza A, Gezer S, Mundie S, Gao X-Z, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus. B, Khan, Z, Chaney C, Showel, J, Gregory S, Preisler H: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268, 1995
27. Raza A, Mundle S, Iftikhar A, Gregory S, Marcus B, Khan Z, Alvi S, Shetty V, Dameron S, Wright V, Adler S, Loew J, Shott S, Ali N, Preisler H: Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 48:143,1995
28. Han JH, Gileadi C, Rajapaksa R, Kosek J, Greenberg PL: Modulation of apoptosis in human myeloid leukemic cells by GM-CSF. Exp Hematol 23:265, 1995
29. Ormerod MG: Analysis of DNA. General methods, in Ormerod MG (ed): Flow Cytometry. A Practical Approach. Oxford, UK, IRL, 1990 pp 69-86
30. Koury MJ: Programmed cell death (apoptosis) in hematopoiesis. Exp Hematol 20:391, 1992
31. Koury MJ, Bondurant MC: Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248:378, 1990
32. Rodriguez-Tarduchy G, Collins M, Lopez-Rivas A: Regulation of apoptosis in interleukin-3 dependent hemopoietic cells by interleukin-3 and calcium ionophores. EMBO J 9:2997, 1990
33. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR: Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 343:76, 1990
34. Sachs L, Lotem J: Control of programmed cell death in normal and leukemic cells: New implications for therapy. Blood 82:15, 1993
35. Negrin RS, Haeuber DH, Nagler A, Olds LC, Donlon T, Souza L, Greenberg PL: Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 110:976, 1989
36. Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T, Vincent M, Greenberg PL: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor. Blood 76:36, 1990
37. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL: Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737, 1993
38. Nagler A, Ginzton N, Negrin R, Bangs D, Donlon T, Greenberg P: Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony-stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes. Leukemia 4:193, 1993
39. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620, 1985
40. Greenberg PL, Baker S, Link M, Minowada J: Immunologic selection of hemopoietic precursor cells utilizing antibody-mediated plate binding ("panning"). Blood 65:190, 1985
41. Hulette BC, Banavali SD, Finke DP, Gopal V, Preisler HD: Proto-oncogene expression in subpopulations of cells from leukemia patients. Cytometry 13:653, 1992
42. Cazzola M, Barosi G, Berzuini C, Dacco M, Orlandi E, Stefanelli M, Ascari E: Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes. Br J Haematol 50:55, 1982
43. Delia D, Aiello DS, Soligo D, Fontanella E, Melani C, Pezzella F, Pierrotti MA, Porta GD: Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 79:1291, 1992
44. Lotem J, Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotheraphy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 4:41, 1993
45. Kastan MB, Stone KD, Civin CI: Nuclear oncoprotein expression as a function of lineage, differentiation stage and proliferative status of normal human hematopoietic cells. Blood 74:1517, 1989
46. Bradbury DA, Russell, NH: Comparative quantitative expression of bcl-2 by normal and leukemic myeloid cells. Br J Haematol 91:374, 1995
47. Davis RE, Greenberg PL: Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: immunostaining of bone marrow biopsies. Blood 84:314a, 1994 (abstr, suppl 1)
48. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G: Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 9:1191, 1995
49. Campos L, Rouault J-P, Sabiolo O, Oriol P. Roubi N, Vasselan C, Archimbaud E: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091, 1993
50. Bradbury D, Zhu Y-M, Russell N: Regulation of bcl-2 expression and apoptosis in acute myeloblastic leukemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia 8:786, 1994
51. Hellstrom-Lindberg E, Birgegrad G, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Merk K, Tangen JM, Winqvist I, Ost A: A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11:221, 1993
52. Negrin R, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg P: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood 87:4076, 1996
53. Rinaudo MS, Su K, Falk LA, Halder S, Mufson RA: Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood 86:80, 1995
54. Jacobs A, Janowska A, Caro J, et al: Circulating erythropoietin levels in patients with myelodysplastic syndrome. Br J Haematol 73:36, 1989
55. Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA: Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 6:1268, 1992
56. Greenberg PL, MacKichan ML, Negrin R, Renick M, Ginzton N: Production of granulocyte colony stimulating factor by normal and myelodysplastic syndrome peripheral blood cells. Blood 76:146, 1990 (suppl 1)
57. Klefstrom J, Vastrik I, Saksela E, Valle J, Eilers M, Alitalo K: c-Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha. EMBO J 13:3442, 1994
58. Reed JC, Tsujimoto Y, Alpers JD, Croce CM, Nowell PC: Regulation of bcl-2 protooncogene expression during normal human lymphocyte proliferation. Science 236:1298, 1987
59. Boise LH, Gonzales-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597, 1993
60. Oltval ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609, 1993
61. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293, 1995
62. Larsen CJ: The Bcl-2 gene. Prototype of a gene family that controls programmed cell death (Apoptosis). Ann de Genetique 37:121, 1994